Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 5/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.37 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.36 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | ME2 | P23368 | 1/20 | 0.35 |
| ▸ | ME1 | P48163 | 1/20 | 0.35 |
| ▸ | ME3 | Q16798 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14694277 | 0.85 | S1PR1 (0.40) | CHRM4 | |
| SCHEMBL16371697 | 0.85 | GFER (0.47) | NR1H2AGTR2SLC6A7CTSBCTSS | |
| SCHEMBL29252729 | 0.85 | AGTR2 (0.48) | NR1H2NR1H3CHRM4AGTR2SLC6A7 | |
| SCHEMBL4225875 | 0.83 | AKR1C3 (0.40) | NR1H2NR1H3CHRM4AGTR2SLC6A7 | |
| SCHEMBL21997577 | 0.82 | CA2 (0.42) | AGTR2 | |
| SCHEMBL17923089 | 0.81 | AGTR2 (0.37) | NR1H2NR1H3AGTR2SLC6A7CTSB | |
| SCHEMBL15009155 | 0.81 | OPRK1 (0.37) | NR1H2NR1H3CHRM4AGTR2ITGB3 | |
| SCHEMBL28036150 | 0.81 | HTR1A (0.48) | FAAH | |
| SCHEMBL4757742 | 0.81 | ALDH1A1 (0.47) | AGTR2SLC6A7NOTUM | |
| SCHEMBL21224830 | 0.80 | SLC6A7 (0.40) | AGTR2SLC6A7ITGB3ITGA2BCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960556-B2 | Thiadiazole derivatives for the treatment of neuro-degenerative diseases | NV REMYND (BE) | 2011-06-14 | — | — | US | disclosed |
| EP-2094677-B1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | REMYND NV (BE) | 2011-01-12 | — | — | EP | disclosed |
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | SNCA, PARK7, PRNP | NR1H2 3180/4885NR1H3 3422/4885CHRM4 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.